Brought to you by 
Hoechst, Vertex expand ICE alliance
22 Jan 2002
Executive Summary
Hoechst has obtained an exclusive worldwide license from Vertex (small molecule drugs) to develop, manufacture, and market Phase I HMR 3480/VX-740 as a therapy for rheumatoid arthritis and an exclusive option for all other compounds discovered under a previous agreement.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com